↓ Skip to main content

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

Overview of attention for article published in Targeted Oncology, November 2020

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter
6 X users
patent
2 patents

Readers on

mendeley
17 Mendeley